About Lantheus Holdings
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company's portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company's Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company's imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: LNTH
- Previous Close: $9.45
- 50 Day Moving Average: $8.86
- 200 Day Moving Average: $8.50
- 52-Week Range: $1.82 - $10.85
- Trailing P/E Ratio: 11.26
- Foreward P/E Ratio: 12.27
- P/E Growth: 0.96
- Market Cap: $337.59M
- Outstanding Shares: 35,724,000
- Beta: 0.29
- Net Margins: 8.64%
- Return on Equity: -12.81%
- Return on Assets: 8.24%
Companies Related to Lantheus Holdings:
- Debt-to-Equity Ratio: -2.43%
- Current Ratio: 2.82%
- Quick Ratio: 2.41%
What is Lantheus Holdings' stock symbol?
Lantheus Holdings trades on the NASDAQ under the ticker symbol "LNTH."
Where is Lantheus Holdings' stock going? Where will Lantheus Holdings' stock price be in 2017?
5 analysts have issued twelve-month target prices for Lantheus Holdings' shares. Their predictions range from $4.00 to $13.00. On average, they expect Lantheus Holdings' share price to reach $10.00 in the next year.
When will Lantheus Holdings announce their earnings?
Lantheus Holdings is scheduled to release their next quarterly earnings announcement on Monday, February, 20th 2017.
Who owns Lantheus Holdings stock?
Lantheus Holdings' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Numeric Investors LLC (5.70%), Partners Group Holding AG (2.57%), Marshall Wace LLP (1.28%), Renaissance Technologies LLC (1.10%), Bogle Investment Management L P DE (0.87%) and Oxford Asset Management (0.85%).
Who bought Lantheus Holdings stock? Who is buying Lantheus Holdings stock?
Lantheus Holdings' stock was acquired by a variety of institutional investors in the last quarter, including Partners Group Holding AG, Oxford Asset Management, Renaissance Technologies LLC, Russell Investments Group Ltd., Marshall Wace LLP, GSA Capital Partners LLP, Ativo Capital Management LLC and Bogle Investment Management L P DE.
How do I buy Lantheus Holdings stock?
Shares of Lantheus Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Lantheus Holdings stock cost?
One share of Lantheus Holdings stock can currently be purchased for approximately $9.45.